Kymab’s main product is a potential treatment for eczema that is going through clinical trials. Photograph: iStock

One of Dublin-listed life science investment company Malin’s key holdings has signalled it plans to float on the stock market in the US. Biopharmaceu(...)

Ian Curley is a veteran of both Ardagh and Smurfit Kappa. Photograph: Dara Mac Dónaill

Life sciences investment company Malin’s chairman of less than a year, Ian Curley, has signalled that he plans to step down from the board as the busi(...)

Malin’s investee company Poseida Therapeutics has filed for a potential IPO.

Life sciences investment company Malin said on Monday that its investee company Poseida Therapeutics has filed for a potential initial public offering(...)

Malin has recently had a board and management overhaul and is now headed by Ian Curley. Photograph:  Dara Mac Donaill

Life sciences investment firm Malin Corporation, which has seen its share price tumble as much as 60 per cent since its 2015 flotation, has pledged to(...)

Ian Curley and other executives are  due to present details of the group’s review at a capital markets day in London early next month

Dublin-listed life sciences investment firm Malin has announced the departure of chief executive Adrian Howd after just one year in the post. The tro(...)

Can Ian Curley save the day at Malin? Photograph: Dara Mac Dónaill

Call it a case of shareholder activism that couldn’t be bothered with the sea view. State-backed life sciences investment firm Malin Corporation’s an(...)

Ian Curley (right) was appointed chairman of Malin in July.

Dublin-based life sciences investment firm Malin said the value of its investment portfolio rose to €402 million in the six months to June 30th. The (...)

Under the terms of the transaction, Malin has invested $20 million in Poseida with a commitment to invest a further $10 million next year subject to the achievement of certain milestones

Malin, the Irish-based company set up by a number of former Elan executives to invest in privately held life science assets, is to take a 31 per cent (...)